Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

George Sgouros, Robert Hobbs, Francis B. Atkins, Douglas Van Nostrand, Paul W Ladenson, Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.

Original languageEnglish (US)
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume38
Issue numberSUPPL. 1
DOIs
StatePublished - May 2011

Fingerprint

Thyroid Neoplasms
Positron-Emission Tomography
Anatomy
Radiopharmaceuticals
Individuality
Neoplasms
Therapeutics
Software
Pharmacokinetics
Electrons

Keywords

  • Positron emission tomography
  • Radioiodine therapy
  • Three-dimensional radiobiological dosimetry
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer. / Sgouros, George; Hobbs, Robert; Atkins, Francis B.; Van Nostrand, Douglas; Ladenson, Paul W; Wahl, Richard L.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. SUPPL. 1, 05.2011.

Research output: Contribution to journalArticle

@article{3f5636ad2beb4751bd325011645ea26d,
title = "Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer",
abstract = "Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.",
keywords = "Positron emission tomography, Radioiodine therapy, Three-dimensional radiobiological dosimetry, Thyroid cancer",
author = "George Sgouros and Robert Hobbs and Atkins, {Francis B.} and {Van Nostrand}, Douglas and Ladenson, {Paul W} and Wahl, {Richard L.}",
year = "2011",
month = "5",
doi = "10.1007/s00259-011-1769-1",
language = "English (US)",
volume = "38",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

AU - Sgouros, George

AU - Hobbs, Robert

AU - Atkins, Francis B.

AU - Van Nostrand, Douglas

AU - Ladenson, Paul W

AU - Wahl, Richard L.

PY - 2011/5

Y1 - 2011/5

N2 - Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.

AB - Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.

KW - Positron emission tomography

KW - Radioiodine therapy

KW - Three-dimensional radiobiological dosimetry

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=79957962933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957962933&partnerID=8YFLogxK

U2 - 10.1007/s00259-011-1769-1

DO - 10.1007/s00259-011-1769-1

M3 - Article

C2 - 21484384

AN - SCOPUS:79957962933

VL - 38

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - SUPPL. 1

ER -